News and Events

July 30, 2018
Immunomedics announces multiple clinical and preclinical collaborations with prominent cancer research institutions
July 23, 2018
Immunomedics announces clinical collaboration with AstraZeneca in first-line triple-negative breast and urothelial cancers
July 18, 2018
FDA accepts biologics license application for filing and grants priority review for sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer
December 4, 2018 - December 8, 2018
SABCS – San Antonio Breast Cancer Symposium
November 16, 2018 - November 18, 2018
PARIS BC 2nd Annual European Congress on Breast Cancer
November 1, 2018 - November 3, 2018
16th Annual School of Breast Oncology
October 19, 2018 - October 23, 2018
ESMO – European Society for Medical Oncology Congress
October 11, 2018 - October 14, 2018
Lynn Sage Breast Cancer Symposium
August 11, 2018 - August 11, 2018
Best of ASCO
August 4, 2018 - August 4, 2018
Best of ASCO
July 27, 2018 - July 28, 2018
17th Annual International Congress on the Future of Breast Cancer – East
July 13, 2018 - July 14, 2018
17th Annual International Congress on the Future of Breast Cancer – West
June 13, 2018
Immunomedics announces pricing of public offering of common stock
June 11, 2018
Immunomedics announces proposed public offering of common stock
June 04, 2018
Immunomedics provides business update at the ASCO 2018 investor event
June 03, 2018
Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers
Immunomedics Reveals Promising Data for Sacituzumab Govitecan in Patients Heavily Pretreated for Metastatic Estrogen Receptor-Positive Breast Cancer
June 01, 2018
Immunomedics announces pivotal study of sacituzumab govitecan in patients with locally advanced or metastatic urothelial cancer
May 30, 2018
Immunomedics to present at Jefferies 2018 Global Healthcare Conference
May 21, 2018
Immunomedics submits biologics license application for sacituzumab govitecan to the U.S. Food and Drug Administration
May 09, 2018
Immunomedics announces third quarter fiscal 2018 results and provides corporate update
May 02, 2018
Immunomedics to report third quarter fiscal 2018 results and host conference call and webcast
April 25, 2018
Immunomedics announces oral presentation of sacituzumab govitecan in hormone receptor-positive (HR+) metastatic breast cancer (mBC) at 2018 American Society of Clinical Oncology (ASCO) annual meeting
April 09, 2018
Immunomedics appoints Dr. Robert Iannone head of Research & Development and Chief Medical Officer
March 05, 2018
Immunomedics to Present at Cowen and Company 38th Annual Health Care Conference
February 15, 2018
Immunomedics to Participate in RBC Capital Markets 2018 Global Healthcare Conference
February 08, 2018
Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update
February 06, 2018
Immunomedics to Report Second Quarter Fiscal 2018 Results and Host Conference Call and Webcast on February 8, 2018
June 1, 2018 - June 5, 2018
2018 ASCO annual meeting
January 11, 2018
Immunomedics Announces Agreement with University of Wisconsin Carbone Cancer Center to Expand Sacituzumab Govitecan (IMMU-132) into Prostate Cancer
January 08, 2018
Immunomedics and Royalty Pharma Announce Royalty Funding and Stock Purchase Agreements Totalling $250 Million
January 04, 2018
Immunomedics to Present at the 36th Annual J.P. Morgan Healthcare Conference